Company*
(Symbol)

Product

Description

Indication

Status (Date)


CANCER

Micromet AG
(Germany)*

MT103

Bispecific antibody
derivative

B-cell lymphoma

Company started a multicenter Phase I trial (2/13**)

Oxford Bio-
Medica plc
(UK; LSE:OXB)

MetXia and TroVax

Cancer gene therapy products; MetXia delivers the gene CYP2B6 directly to solid tumors, where it generates an enzyme that converts the prodrug cyclophosphamide into its active, cytotoxic form; TroVax is based on a gene for the tumor-associated antigen OBA1

Breast cancer and colorectal cancer

Company said the products achieved positive interim results from Phase I/II trials (2/27**)

PhotoCure ASA
(Norway; OSE:PH)

Metvix PDT

Photodynamic therapy

Basal cell carcinoma and actinic keratosis

Company received approval in Norway for Metvix PDT (2/1); received marketing authorization in New Zealand (2/8)

Viragen Inc.
(AMEX:VRA)

-

Natural interferon

Malignant melanoma

Phase II/III results from a German study indicated the probability of relapse-free survival after five years was doubled in the treated patients (2/28)

Xenova Group
plc
(UK; XNVA)

XR11576

DNA targeting agent

Solid tumors

Phase I trial began in the Netherlands and the UK (2/5)

CARDIOVASCULAR

Actelion Ltd.
(Switzerland; SWX:ATLN)

Tracleer

Orally active endothelin
receptor antagonist

Pulmonary arterial hypertension

The European Union's Committee for Proprietary Medicinal Products issued a positive opinion on Tracleer tablets (2/22)

CENTRAL NERVOUS SYSTEM

Neurobiological
Technologies Inc.
(NTII) and Merz Pharma KgaA (Germany)

Memantine by modulating the N-methyl D-aspartate receptor on cell membranes

Oral neuroprotective agent that appears to restore damaged nerve cells and block excitatory signals

Alzheimer's disease

Company was granted approvable status from regulatory authorities in the European Union (2/22)

INFECTION

Achillion Pharma-
ceuticals
Inc.*

ACH-126,443

L-nucleoside antiviral agent administered orally once
daily

Chronic hepatitis B

Company began a Phase II study, which will be conducted in Europe (2/28)

Cubist Pharma-
ceuticals
Inc. (CBST)

Cidecin

Daptomycin for injection

Urinary tract infection caused by Gram- positive bacteria

In an Eastern European Phase II trial, Cidecin was found to be 83% effective in the evaluable population (2/14)

Gilead Sciences
Inc.
(GILD)

Viread

Tenofovir disoproxil
fumarate

HIV infection

The European Medicines Evaluation Agency granted marketing authorization for Viread in the European Union (2/7)

Immunitor Co.*

V-1 Immunitor

Vaccine

HIV

Study results showed evidence of clinical benefit; the vaccine has been given to more than 50,000 AIDS patients in Thailand (2/7)

Tibotec-Virco
NV
(Belgium)*

TMC125

A next-generation, non-nucleoside reverse transcriptase inhibitor

HIV

Efficacy data from a Phase IIa trial in Europe demonstrated significant antiviral activity in HIV patients infected with NNRTI-resistant virus and failing NNRTI therapy (2/28)

INFLAMMATION AND PAIN

Amrad Corp.
Ltd.
(Australia; ASX:AMC)

AM336

Synthetic version of the molecule CVID, originally isolated from the venom of a fish-eating species of cone snail from Australia's Great Barrier Reef

Chronic
severe pain

Company said positive findings from a multicenter Phase I/II trial in Australia led to early completion, and plans more safety studies and a full Phase II trial this year (2/28)

MISCELLANEOUS

Discovery Laboratories
Inc.
(DSCO)

Surfaxin

Humanized, synthesized peptide containing surfactant

Acute lung injury

Company was awarded orphan drug product designation in Europe (2/15)

DOR BioPharma Inc. (AMEX:DOR)

orBec

Beclomethasone
dipropionate

Intestinal graft-vs.-host disease

OrBec received orphan medicinal product designation in Europe (2/28)

Metabolic Pharmaceuticals Ltd. (Australia; ASX:MBP)

AOD9604

Injection; human growth hormone

Obesity

Phase IIa results showed significant effects on the weight of the clinically obese participants (2/13**)

Scil biomedicals GmbH
(Germany)*

SMART anti-L-selectin antibody

Humanized compound

Trauma

Company completed enrollment in an international, multicenter Phase II trial (2/13**)

Transgene
SA
(France;
TRGNY)

MVA-HPV-IL2 pox virus, to express two human papillomavirus antigens found in HPV 16, the E6 and E7 proteins

Vaccine that uses the MVA vector, a highly attenuated neoplasia

Cervical intraepithelial

Company initiated a Phase II trial at six sites in France (2/28)


Notes:

* Privately held

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OSE = Oslo Stock Exchange; SWX = Swiss Stock Exchange